Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sheetal Chandhok

Cardiovascular Disease Bryn Mawr, PA Medical Doctor

NPI 1720177173 CMS profile 350369

825 Old Lancaster Rd, Suite 320, Bryn Mawr, PA 19010

Open in the dashboard

General payments

$190,951

757 records reported · program years 2019–2025

Research payments

$575

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$657,159 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Sheetal Chandhok of Bryn Mawr, PA is reported in the CMS Open Payments database as having received $190,951 across 757 general payments and $575 in research payments paid to them. Separately, studies naming them as principal investigator received $657,159 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $17,422 94
2024 General $2,646 95
2023 General $3,091 117
2022 General $30,470 167
2021 General $47,594 103
2020 General $46,897 57
2019 General $42,831 124
2019 Research $575 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sheetal Chandhok
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Sheetal Chandhok were reported at $17,422. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Sheetal Chandhok Cardiovascular Disease median Middle half National median
2019 $42,831 $450 $127–$1,392 $163
2020 $46,897 $242 $77–$751 $114
2021 $47,594 $335 $101–$1,037 $132
2022 $30,470 $395 $121–$1,211 $149
2023 $3,091 $443 $136–$1,283 $160
2024 $2,646 $450 $136–$1,323 $164
2025 $17,422 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $88,363 68 payments
  2. Boston Scientific Corporation $28,034 235 payments
  3. Impulse Dynamics (USA) Inc. $26,426 36 payments
  4. Atricure, Inc. $20,085 27 payments
  5. Respicardia, Inc. $15,675 14 payments
  6. Abbott Laboratories $5,854 63 payments
  7. Novartis Pharmaceuticals Corporation $1,264 65 payments
  8. Abiomed $1,033 21 payments
  9. Pfizer Inc. $805 54 payments
  10. Amgen Inc. $437 26 payments
  11. Other $2,974 148 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $122,982 35 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $38,450 19 payments
  3. Food and Beverage $17,121 689 payments
  4. Honoraria $5,800 3 payments
  5. Travel and Lodging $4,098 10 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $2,500 1 payment
Products named General payments · program years 2019–2025
  1. XARELTO $88,363 68 payments
  2. remede System $15,675 14 payments
  3. General - EP $15,000 6 payments
  4. OPTIMIZER SMART SYSTEM Cardiovascular Device $14,150 2 payments
  5. LARIAT SUTURE DELIVERY DEVICE Cardiovascular $11,272 8 payments
  6. LARIAT SUTURE DELIVERY DEVICE Cardiovascular $7,069 8 payments
  7. Optimizer Cardiovascular $6,249 12 payments
  8. WATCHMAN $6,188 9 payments
  9. Optimizer Cardiovascular $6,098 10 payments
  10. Optimizer Smart System Cardiovascular Device $5,603 5 payments
  11. Other $22,216 683 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Abbott Laboratories $575 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 51 drugs

Part D claims

4,174

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$1,138,167

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

34.3%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 477 $454,970
Xarelto Rivaroxaban Brand 453 $423,317
Dofetilide Generic 374 $66,175
Entresto Sacubitril/Valsartan Brand 49 $61,056
Mounjaro Tirzepatide Brand 34 $37,473
Praluent Pen Alirocumab Brand 19 $13,134
Repatha Sureclick Evolocumab Brand 20 $12,088
Jardiance Empagliflozin Brand 15 $11,295
Flecainide Acetate Generic 216 $8,413
Metoprolol Succinate Generic 431 $7,175

The 10 drugs with the highest cost, of 51 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 114 billing codes

Paid by Medicare

$1,027,888

Of which drugs: $2,050

Medicare patients

1,484

Average age 78

Services billed

11,685

720 women, 764 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 62%
Ischemic heart disease 61%
Arthritis 54%
Heart failure 36%
Chronic kidney disease 31%
Diabetes 29%
Depression 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 92 368 $1,964

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FUROSCIX
  • SCPHARMACEUTICALS INC. $127
$127 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $79
$79 — —
AMVUTTRA
  • Alnylam Pharmaceuticals Inc. $71
$71 — —
Repatha
  • Amgen Inc. $62
$62 20 —
ELIQUIS
  • PFIZER INC. $44
  • E.R. Squibb & Sons, L.L.C. $18
$62 477 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

758 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record